Introduction {#S1}
============

The unceasing proliferation of pathogenic resistance among key human GI pathogens, for example, the appearance of drug-resistant *Staphylococci*, *Enterococci*, *Klebsiella pneumoniae*, and *Pseudomonas* spp., leads to prolonged illness and a risk of death ([@B40]). Moreover, excessive application of antibiotics has further selected for vertical and horizontal dissemination of many antibiotic resistance markers across multiple strains and species. Thus, it is essential to find new antimicrobial agents that are not affected by traditional mechanisms of bacterial resistance. Antimicrobial peptides (AMPs) often behave like hormones or even as medicines with antimicrobial, antihypertensive, immunomodulatory, opioid, and antioxidant activities. For example, alpha-melanocyte stimulating hormone (α-MSH), a short cationic peptide, was a strong potential anti-infective agent ([@B38]). Additionally, 60 therapeutic peptides have been approved by US Food and Drug Administration (FDA) as antibodies, vaccines, and antimicrobial agents, etc. ([@B1]). These peptides provide microbicidal activity via physical disruption of a pathogen's membrane and subsequent leakage of cytoplasmic components, which greatly reduces the development of bacterial resistance because it is metabolically costly for the bacteria to mutate or repair the membrane's molecular constituents ([@B26]; [@B45]; [@B31]; [@B25]; [@B18]; [@B13]). Thus, AMPs can also be widely used in agriculture and the food industry to replace the long-term and indiscriminate use of pesticides and antibiotics ([@B48]). Probiotics, such as lactic acid bacteria (LAB) or bifidobacteria, have tremendous potential for development of healthy diets, treatment, and prevention ([@B5]). Thus, pathogen-specificity is a major property, in addition to high resistance to degradation, low toxicity toward the host and low production cost, for next-generation antimicrobials ([@B16]; [@B42]). Since *Staphylococcus epidermidis*, *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa* are all prevalent pathogens in implant-associated infections ([@B4]), peptides with activity against these pathogens instead of probiotics have great potential.

It is well-known that sequence parameters such as amino acid frequency, hydrophobicity, charge ratio, structure could be modified to achieve ideal functions ([@B37]). Furthermore, the previous research demonstrated that composition of amino acids largely accounted for the antimicrobial spectrum in an active template ([@B29]; [@B52]). Thus, tryptophan, which showed a real ability to enhance peptide aggregation in solution and on a bilayer surface via π--π interactions and to increase membrane insertion and disruption, was first selected to ensure hydrophobicity ([@B51]; [@B9]). Additionally, [@B49] reported that a Trp triplet stabilized by both aromatic-aromatic and aromatic-aliphatic interactions, shown as a WWW motif, can be applied to generate bacteria-targeting sequences. Following this Trp motif, a positive-charged amino acid arginine (Arg), which causes toroidal pore defects in the anionic membrane and positively influences electrostatic interactions between peptides and the negatively charged bacterial membrane surface ([@B9]), was added to obtain amphipathic sequences. Our research indicated a vital role of the hydrophilic amino acid to adjust the antibacterial spectrum but its exact effect was not distinguished ([@B10]). Finally, the resulting primary peptide structure simplified as RRWyWWWyWRR, where y represents an uncharged hydrophilic amino acid ([Schema 1](#CS1){ref-type="fig"}) was proposed as a probiotic-neutral sequence. All peptides were amidated to increase their stabilization and net charge. The overall objective of this study was to facilitate the development of peptide-based synthetic strategies to generate selective-function bioactive agents.

![General schematic of designed peptides.](fmicb-11-00537-g007){#CS1}

Materials and Methods {#S2}
=====================

Materials {#S2.SS1}
---------

Mueller-Hinton broth (MHB), Mueller-Hinton agar (MHA) and MRS powder were obtained from AoBoX (China). Bovine serum albumin (BSA), Triton X-100, polymyxin B, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), dimethyl sulfoxide (DMSO), BODIPY-TR-cadaverine (BC), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 3,3′-dipropylthiadicarbocyanine (disc~3--5~), ethanol (analytical grade, 99%), tertiary butanol (analytical grade, 99%), acetone (analytical grade, 99%), glutaraldehyde (synthetic grade, 50% in H~2~O), lipoteichoic acid (LTA) from *S. aureus* and lipopolysaccharide (LPS) from *E. coli* were purchased from Sigma-Aldrich (China). Phosphate-buffered saline (PBS) solution, sodium chloride, potassium chloride, ammonium chloride, calcium chloride, zinc chloride, magnesium chloride, and ferric chloride were purchased from Kermel (China). Glucose (analytical grade) was obtained from Zhiyuan (Guangdong, China). DMEM phenol red-free medium and fetal bovine serum were purchased from Gibco (Beijing, China). All these reagents were used according to the required concentration range.

Bacterial Strains {#S2.SS2}
-----------------

The bacteria strains *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, *Staphylococcus aureus* ATCC 29213, *Escherichia coli* UB 1005, methicillin-resistant *Staphylococcus aureus* (MRSA) ATCC 43300 and *Staphylococcus epidermidis* ATCC 12228 were obtained from the College of Veterinary Medicine, Northeast Agricultural University. *L. plantarum* 8014, *Lactobacillus rhamnosus* 1.0386, *L. rhamnosus* 7469, *L. rhamnosus* 1.0911, *L. rhamnosus* 1.0385, and *L. rhamnosus* 1.0925 were obtained from the Key Laboratory of Food College, Northeast Agricultural University.

Peptide Synthesis and Sequence Analysis {#S2.SS3}
---------------------------------------

The peptides designed in this study were synthesized by Sangon Biotech, Co., Ltd. (Shanghai, China), and the molecular masses of these peptides were determined using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Linear Scientific, Inc., United States), with α-cyano-4-hydroxycinnamic acid as the matrix. The purity of the peptides (95%) was assessed by reversed-phase high-performance liquid chromatography (HPLC) using a Shimdzu Inertsil ODS-SP column (4.6 mm × 250 mm, 214 nm, 20 μL) and a non-linear water/acetonitrile gradient containing 0.1% trifluoroacetic at a flow rate of 1.0 mL/min.

Cytotoxicity Measurements {#S2.SS4}
-------------------------

The cytotoxicity of the peptides was determined with three cell types, namely, fresh, healthy human erythrocytes (obtained from a healthy donor Jiawei Li); murine macrophage cell line RAW264.7 cells; and human embryonic kidney (HEK) 293T cells, via hemolysis and MTT dye reduction assays. The release of hemoglobin and MTT dye reduction were monitored by measuring the absorbance at 570 nm. The tests were performed at least three times.

MIC Measurements {#S2.SS5}
----------------

The antibacterial activity of the peptides was measured using a method adopted from the Clinical Laboratory Standards Institute (CLSI), with modifications. 50 μL bacterial cells solution with 1000-fold of OD~600~ = 0.4 was mixed with 50 μL of each peptide of various concentration ranged from 2 to 64 μM dissolved in BSA (0.2% with 0.01% acetic acid) and incubated in sterile 96-well plates at 37°C for 24 h. The MICs were calculated as the lowest concentration of peptide with no microbial growth being observed. Broth with microbial cells and uninoculated broth were used as positive control and negative control, respectively. The tests were performed at least three times.

Salt and Serum Sensitivity Assay {#S2.SS6}
--------------------------------

Different final concentrations of physiological salts (150 mM NaCl, 4.5 mM KCl, 6 μM NH~4~Cl, 8 μM ZnCl~2~, 1 mM MgCl~2~, and 4 μM FeCl~3~) and serum (50, 25, 12.5%) was mixed into Mueller-Hinton broth (MHB) to determine sensitivity of peptides to the salt and serum against *E. coli* ATCC 25922 and *S. aureus* ATCC 29213. The subsequent steps were consistent with the MIC determination method.

Timed Killing Curve and Fractional Survival Tests {#S2.SS7}
-------------------------------------------------

The ability of peptides to kill bacterial cells was further investigated by analyzing the fractional cell survival upon peptide treatment at various exposure times to show the dramatic differences in killing speed between comparable peptides. Briefly, *E. coli* ATCC 25922 or *S. aureus* ATCC 29213 (0.5--1 × 10^6^ CFU/mL) was treated at the 1/2, 1, and 2 MIC of peptides. At various time periods (0, 5, 10, 30, 60, 120 min), microbial suspensions were diluted 10- and 100-fold, and then 50 μL diluted suspension was plated on MHA plates. Microbial colonies were formed and counted after 24 h of incubation. The data presented in the results are the means from three independent assays.

Drug Resistance Experiment {#S2.SS8}
--------------------------

Resistance development of *E. coli* ATCC 25922 against antibiotics was investigated using a sequential passaging method. Briefly, in the first generation, the MIC value was determined as described previously. After a 24 h incubation, bacterial cells growing in a well with a half-MIC level were harvested and diluted to 0.05 at OD~600~, followed by a 1:10 dilution in fresh MHB. The inoculum was subjected to subsequent passage MIC testing, and the process was repeated for 30 days. The fold change in MIC was plotted against the number of passages.

Antimicrobial Mechanism Measurement {#S2.SS9}
-----------------------------------

The mechanism of the designed peptides was measured by fluorescence spectroscopy and electron microscopy as shown before. The fluorescent dyes disc~3~-~5~, β-galactosidase, calcein and BC were used to determine cytoplasmic membrane depolarization and the binding affinities of the peptides to LPS and LTA ([@B44]; [@B10]). Briefly, for depolarization, 0.4 μM disc~3~-~5~ was added to the bacteria, which were washed and diluted into an OD600 of 0.05 with 5 mM HEPES buffers (containing 20 mM glucose and 0.1 KCl); for inner membrane permeability, bacteria incubated in LB containing 2% lactose were washed and diluted to an OD600 of 0.05 with 10 mM PBS (pH 7.4) containing 1.5 mM ONPG; for LPS or LTA binding, LPS/LTA and BC were mixed in Tris buffer (50 mM, pH 7.4) with a final concentration of 50 and 5 μg/ml, respectively. Four hours later, the probe mixture was added to 96-well containing peptides with various concentration and incubated for 1 h. The fluorescence levels indicated ROS production, which was reported as important for the apoptosis-like death in bacteria since ROS can destroy all three major classes of macromolecules and compromise cell viability. And we tested the intracellular production of ROS by 2′, 7′-dichlorofluorescin diacetate (DCFH-DA) with bacteria of OD600 = 0.6 and DCFH-DA = 10 μM incubating for 1 h at 37°C ([@B27]; [@B20]). In addition, SEM, TEM, and CLSM were used to obtain direct visualization of bacterial membrane damage ([@B43]; [@B10]), and the bacteria samples (OD~600~ = 0.05) were treated with 1 × MIC peptide for half an hour.

Mouse Model and Cytokine Assay {#S2.SS10}
------------------------------

Female Institute for Cancer Research (ICR) mice (SPF, 20--25 g) were purchased from WeiTonglihua, Co., Ltd. (Beijing, China). Mice were fed and acclimatized as described ([@B10]). *E. coli* ATCC 25922 was adopted as the pathogenic bacterium for the infection model in this study. In this mouse model, the antimicrobial activity of S7 was determined by colony counting of blood and various organs. Briefly, the mice were divided into four groups (six groups for anti-inflammatory assay) and received intraperitoneal injections of 100 μl *E. coli* (1 × 10^8^ CFU/ml) cells in 0.9% NaCl or only 100 μl 0.9% NaCl as control. 1 h later, 100 μl S7 (5 mg/kg), 100 μl 0.9% NaCl, 100 μl gentamicin (5 mg/kg) or 100 μl 0.9% NaCl, was intraperitoneally injected to the treated or control groups, respectively. And the mice were sacrificed via excessive anesthesia after 6 h post-challenge. The anti-inflammatory effect of S7 was measured by testing the levels of TNF-α, IL-6, and IL-1β in serum using a TNF-α enzyme-linked immunosorbent assay (ELISA) kit, an IL-6 ELISA kit and an IL-1β ELISA kit according to the manufacturer's instructions (Shanghai Jin Ma Laboratory Equipment, Co., Ltd.).

Statistical Analysis {#S2.SS11}
--------------------

The statistical significance of the experimental results was determined by a one-way ANOVA, followed by Duncan's test. Values of ^∗^*P* \< 0.05 were considered statistically significant. GraphPad Prism version 6.0 (San Diego, CA, United States) was used for all statistical analyses.

Results {#S3}
=======

Design and Characterization of the Peptides {#S3.SS1}
-------------------------------------------

The fidelity, purity and molecular weights of the peptides were verified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Linear Scientific, Inc., United States) and reverse-phase high-performance liquid chromatography (RP-HPLC), which indicated that the measured molecular weights of the peptides were close to their theoretical molecular weights ([Table 1](#T1){ref-type="table"}) and that the purities of the peptides were more than 95%, indicating that successful synthesis of the peptides.

###### 

Peptides design and their key physicochemical parameters.

  Peptide   Sequence          Theoretical MW   Measured MW^a^   Net charge   H^b^
  --------- ----------------- ---------------- ---------------- ------------ -------
  S1        RRWCWWWCWRR-NH2   1780.11          1779.1           5            0.935
  S2        RRWYWWWYWRR-NH2   1900.18          1899.16          5            0.830
  S3        RRWNWWWNWRR-NH2   1802.04          1801.02          5            0.546
  S4        RRWQWWWQWRR-NH2   1830.09          1829.08          5            0.615
  S5        RRWTWWWTWRR-NH2   1775.06          1774.8           5            0.703
  S6        RRWGWWWGWRR-NH2   1686.92          1686.7           5            0.655
  S7        RRWSWWWSWRR-NH2   1747             1746             5            0.648

a

Molecular weight (MW) was measured by mass spectroscopy (MS).

b

H was the total hydrophobicity (sum of all residue hydrophobicity indices) divided by number of residues and calculated from

http://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py

.

Biocompatibility Assays {#S3.SS2}
-----------------------

High biocompatibility is a prerequisite for any bioactive agents to break through clinical application bottlenecks. Thus, the activities of all designed peptides against fresh, healthy human erythrocytes, human embryonic kidney 293T cells and murine macrophage cell line RAW 264.7 cells were first assessed, as shown in [Figure 1A](#F2){ref-type="fig"}, all the designed peptides showed significantly lower hemolytic activities than the typical peptide melittin (*P* \< 0.01). The peptide cytotoxicity against RAW 264.7 cells and HEK 293T cells also confirmed that the cell viabilities after exposure to these peptides were higher than 70% (except for S4 and S6 at 64 μM), which were significantly higher than those after exposure to melittin (*P* \< 0.05).

![Cell toxicity of the peptides against erythrocytes, RAW264.7 and HEK 293T. Statistically significant differences are noted with different letters (*P* \< 0.05) and \*\* represents significant difference compared with Melittin (*P* \<0.01) **(A)**; Fractional microbial survival of *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 29213 treated with S5 and S7 **(B)**; Resistance development in the presence of sub-MIC concentration of S5, S7, gentamicin, and tetracycline **(C)**.](fmicb-11-00537-g001){#F2}

Antimicrobial Activity Assay {#S3.SS3}
----------------------------

The antibacterial activities of these peptides against *Staphylococcus epidermidis*, *Staphylococcus aureus*, *Escherichia coli*, *Pseudomonas aeruginosa* and *Lactobacillus* are shown in [Table 2](#T2){ref-type="table"}, S5 and S7 showed the best activity and specificity among this series, with geometric means (GMs) of 2.24 and 3.17 μM against pathogens, respectively, and more than 64 μM against *Lactobacillus.*

###### 

The MICs of the peptides against pathogenic or probiotic bacteria.

       MICs (μ M)                                                                         
  ---- ------------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  S1   \>64         16     8      8      8      4      \>64   \>64   \>64   \>64   16     8
  S2   32           32     8      8      8      8      \>64   16     \>64   \>64   16     4
  S3   \>64         \>64   \>64   \>64   \>64   \>64   \>64   \>64   \>64   \>64   \>64   \>64
  S4   4            4      4      4      4      4      \>64   64     \>64   \>64   16     8
  S5   2            2      4      2      1      4      \>64   \>64   \>64   \>64   \>64   \>64
  S6   4            2      8      \>64   16     16     \>64   \>64   \>64   \>64   \>64   \>64
  S7   4            2      4      4      4      2      \>64   \>64   \>64   \>64   \>64   \>64

\*Methicillin-resistant

Staphylococcus aureus

.

Time-Kill Curve Assay {#S3.SS4}
---------------------

Based on the above results, the ability of the peptides S5 and S7 to kill the model pathogens *E. coli* 25922 and *S. aureus* 29213 was further investigated by analyzing fractional cell survival upon peptide treatment at the 1/2, 1, and 2 MIC at various exposure times. Our results ([Figure 1B](#F2){ref-type="fig"}) showed that the sterilization rate was dependent on the concentration of the peptide, with higher concentrations having faster rates.

Salt and Serum Susceptibility Assays {#S3.SS5}
------------------------------------

The susceptibility of antimicrobial peptides to salt or a serum environment has prevented many potential peptides from achieving clinical application. Thus, the antimicrobial activities of S5 and S7 against *E. coli* 25922 and *S. aureus* 29213 in the presence of physiological concentrations of different salts or a serum environment were further evaluated. While their antimicrobial activities against *S. aureus* 29213 were retained in the presence of all salts, S5 and S7 retained their antimicrobial activity against *E. coli* 25922 in the presence of most salts except Fe^3+^ and Ca^2+^, with Fe^3+^ increasing the MICs of S5 and S7 up to 8- and 4-fold, respectively, and Ca^2+^ increasing the MIC of S5 up to 4-fold. S5 and S7 showed compromised activity in the serum environment, and the MICs of S5 and S7 increased up to 16- and 4-fold in the presence of 50% serum, respectively ([Table 3](#T3){ref-type="table"}).

###### 

The MIC^a^ values of the peptides against *E. coli* ATCC 25922 and *S. aureus* ATCC 29213 in the presence of physiological salts or serum environment.

  Peptide                                           Control^†^   NaCl^†^   KCl^†^   MgCl~2~^†^   NH~4~Cl^†^   ZnCl~2~^†^   FeCl~3~^†^   CaCl~2~^†^   50% of serum   25% of serum   12.5% of serum
  ------------------------------------------------- ------------ --------- -------- ------------ ------------ ------------ ------------ ------------ -------------- -------------- ----------------
  ***Gram-negative strain E. coli* ATCC 25922**                                                                                                                                    
  S5                                                2            4         4        1            4            1            16           8            32             32             32
  S7                                                4            8         4        8            4            1            16           4            16             16             16
  ***Gram-positive strain S. aureus* ATCC 29213**                                                                                                                                  
  S5                                                1            4         2        1            2            1            4            2            32             8              8
  S7                                                4            4         2        2            2            1            4            2            16             8              4

†

The final concentrations of NaCl, KCl, NH

4

Cl, MgCl

2

, CaCl

2

, ZnCl

2

, and FeCl

3

were 150 mM, 4.5 mM, 6 μM, 1 mM, 2 mM, 8 μM, and 4 μM, respectively, and the control MIC values were determined in the absence of these physiological salts. The data were derived from representative value of three independent experimental trials.

Drug Resistance Assay {#S3.SS6}
---------------------

Drug resistance was induced by treating *E. coli* 25922 with S5 and S7, with gentamicin and tetracycline as controls. As shown in [Figure 1C](#F2){ref-type="fig"}, compared with gentamicin and tetracycline, which induced rapid resistance acquisition, S5 and S7 displayed relatively constant MIC values against these bacterial strains throughout the experiment following serial passaging of bacterial cells in the presence of sub-MICs of the antimicrobial peptides, suggesting that it is difficult for bacteria to acquire resistance to S5 and S7.

Antibacterial Mechanism Study {#S3.SS7}
-----------------------------

In addition to these potential application effect assays, S5 and S7 were further studied for their activity mechanism for killing the model bacteria *E. coli* 25922 and *S. aureus* 29213.

Based upon molecular components of gram-positive and gram-negative bacterial membranes, binding to LPS or LTA located on the outer membrane (OM) was speculated to be the first step of S5 and S7 acting on the bacteria. The experimental result ([Figure 2](#F3){ref-type="fig"}) showed that S5 and S7 could bind to LPS or LTA in a dose-dependent manner. However, compared with the broad-spectrum peptide melittin, S5 and S7 showed a significant reduction in fluorescence intensity (*P* \< 0.05), indicating a lower affinity of these two peptides to LPS or LTA than that of melittin.

![Antibacterial mechanism study Combination of lipopolysaccharide (LPS from *E. coli*) and lipoteichoic acid (LTA from *S. aureus*) with peptides (S5, S7 and Melittin). \* represents significant difference compared with Melittin (*P* \< 0.05).](fmicb-11-00537-g002){#F3}

Subsequently, cytoplasmic membrane perturbation and permeability were further assessed by measuring the cytoplasmic membrane depolarization level and the release of cytoplasmic β-galactosidase. The results ([Figure 3A](#F4){ref-type="fig"}) showed that membrane potential changes in *E. coli* ATCC 25922 and *S. aureus* 29213 induced by the 1/2, 1, and 2 MIC of S5 and S7 were time- and dose-dependent within 1500 s but they were still lower than those induced by melittin. Additionally, the results of the release of cytoplasmic β-galactosidase by *E. coli* UB 1005 ([Figure 3B](#F4){ref-type="fig"}) showed that S5 and S7 induced a rapid release of cytoplasmic β-galactosidase at the 1 and 2 MIC. The release of cytoplasmic β-galactosidase induced by S5 and S7 at their MICs were significantly lower than that induced by melittin (^∗∗^*P* \< 0.01), but they all show similarly cytoplasmic membrane permeability at their 2 MICs (*P* \> 0.01).

![Interaction of Cytoplasmic membrane with peptides (S5, S7 and Melittin) against *E. coli* ATCC 25922 and *S. aureus* 29213 **(A)** and hydrolysis of ONPG due to release of cytoplasmic β-galactosidase of *E. coli* UB 1005 treated by 1/2, 1, and 2×MIC peptides were measured spectroscopically at absorbance of 420 nm as a function of time **(B)**.](fmicb-11-00537-g003){#F4}

Finally, the visualized cell morphology and intracellular ultrastructural alterations of cells treated with S5 and S7 were observed by SEM, TEM, and CLSM. The SEM results ([Figure 4A](#F5){ref-type="fig"}) showed that a control bacterial membrane was intact and smooth, while the bacterial membranes treated with S5 and S7 were roughened and blebby, suggesting that S5 and S7 could induce obvious pore formation and membrane destruction. Observation by TEM ([Figure 4B](#F5){ref-type="fig"}) further suggested that S5 and S7 resulted in obvious alterations of membrane morphology, loss of intracellular contents, and obvious clear areas compared with the dense internal structures of the control group. Furthermore, FITC-labeled peptides were used to monitor peptide localization by Confocal Laser-Scanning Microscopy, and [Figure 4C](#F5){ref-type="fig"} showed that S5 or S7 presented green fluorescent signal distribution around the *E. coli* and *S. aureus* cell surface, indicating that they targeted the cell membrane surface. In addition to these membrane interaction assays; ROS production was tested to determine the apoptosis-like death in bacteria. [Figure 5](#F6){ref-type="fig"} showed that all the tested peptides could induce significant fluorescence increase in the bacteria cells at concentrations higher than MIC.

![Membrane damage effect of *E. coli* ATCC 25922 and *S. aureus* 29213 treated by S5 and S7 was observed by SEM and TEM **(A,B)**; Combination of *E. coli* 25922 and *S. aureus* 29213 with FITC-labeled peptides (S5 and S7) was observed using confocal fluorescence microscope **(C)**.](fmicb-11-00537-g004){#F5}

![The effects of S5, S7 and Melittin on the levels of ROS. Data represents the mean ± SEM. \*\* means *P* \< 0.01 compared with the untreated cells.](fmicb-11-00537-g005){#F6}

*In vivo* Efficacies of the Selective Peptide {#S3.SS8}
---------------------------------------------

To further confirm the *in vivo* antimicrobial effect of the novel designed antimicrobial peptide, S7 was selected to treat the mice infected with *E. coli* ATCC 25922, and the activity was demonstrated by counting bacterial load distribution. And the bacterial colony distribution in the blood, kidney and liver showed that the number of colonies in control group (only injected with twice 100 μl 0.9% NaCl) was none, and the number of colonies in the S7 + *E. coli* and gentamicin + *E. coli* groups were significantly decreased compared with that in the *E. coli* group (*P* \< 0.05) after 6 h post-treatment ([Figure 6A](#F7){ref-type="fig"}). In addition, the inflammatory cytokines were further tested to expose the anti-inflammatory effect of S7, and the levels of the inflammatory cytokines (TNF-α, IL-6, and IL-1β) shown that the serum levels of TNF-α and IL-6 in S7 + *E. coli* group were decreased significantly compared with those of *E. coli* group (*P* \< 0.05) but the S7 + *E. coli* group showed no significant difference in the level of IL-1β compared with the *E. coli* group (*P* \> 0.05) ([Figure 6B](#F7){ref-type="fig"}).

![Bacterial load in blood and major mouse organs **(A)**. Statistically significant differences are noted with different letters (*P* \< 0.05); Effect of S7 on the TNF- α (Left), IL- 6 (Middle), and IL- 1β (Right) levels in the serum (*n* = 6) **(B)**. Data represents the mean ± SEM. Means with different letters represent significantly different at *P* \< 0.05 by Duncan's test.](fmicb-11-00537-g006){#F7}

Discussion {#S4}
==========

Tryptophan (W), which is thought to be able to cross the blood--brain barrier (BBB) in a free form, has been demonstrated to be a non-toxic exogenously supplied amino acid, with a median lethal dose (LD50) as high as 1.6 g/kg in rats, corresponding to ∼ 1.4 g/kg in humans ([@B33]; [@B15]). Also, the indole ring of tryptophan prefers to interact with a polar-polar interface, and the indole NH being close to a lipid carbonyl ester leads W-containing peptides to be powerful and safe promising antibiotic candidates with different beneficial effects ([@B12]; [@B21]). Paired consecutive arginine residues were appended to enhance electrostatic interactions by strong bidentate H-bonds with phosphate moieties from two lipid headgroups and electrostatic cation-π interactions with aromatic residues ([@B28]; [@B17]; [@B41]). Thus, sequences rich in Arg and Trp showed higher antimicrobial activity by forming hydrogen bonds as these peptides associate with membrane components ([@B23]). Moreover, it is well-known that probiotics also take an important role in killing bacteria, modulating intestinal barrier and modulating immune system. Our previous selective-template against Gram-negative has proved that antimicrobial-spectrum of a given peptide could be modified via replacing hydrophilic amino acids ([@B10]). Thus, the final peptide series provided a comparative picture of the effect of different hydrophilic amino acids on the antimicrobial spectrum, depending on the triplet-tryptophan-pivot design.

The toxicity of synthetic peptides against host cells is frequently believed to be the chief limitation of using AMPs as novel therapeutics. The biocompatibility assay results revealed that these triplet-tryptophan-pivot peptides are safe for use in mammals due to their proper hydrophobicity, which was determined to be the most critical structural factor that determines the toxicity of AMPs ([@B36]). In addition, different cell survival rates within the triplet-tryptophan-pivot groups demonstrated that hydrophilic amino acids also significantly affected biocompatibility, which might be due to hydrophilic amino acids changing not only the total hydrophobicity but also the folding structure of the peptides.

Antimicrobial peptides exhibit varying antimicrobial activities against microbes by acting on the target cell membranes via a non-receptor-mediated pathway, making it possible to replace traditional antibiotics; thus, selective activity of peptides is thought to be a challenge for the application of AMPs as future biomaterials without damaging natural probiotic levels. Previous reports demonstrated that the antimicrobial activity of peptides was related to positive charges, amino acid composition, hydrophobicity, residue distribution, and secondary structure ([@B19]; [@B2]). In our study, the surprise result that most of these triplet-tryptophan-pivot peptides (except for S3) possessed efficient antimicrobial activity against pathogenic bacteria, including both Gram-negative and Gram-positive ones, while showing no effect on the tested probiotics even at the highest tested concentration (64 μM) demonstrated that positive charge and hydrophobic amino acid distribution are the key factors in determining the bioactivity of peptides, and this short template containing 4 Arg and 5 Trp residues showed high potential selectivity of antimicrobial agents for maintaining microecological balance ([@B8]). Besides, these seven sequences showed varying degrees of antibacterial activities against tested bacteria, which indicated hydrophilic amino acids a vital role in adjusting the antibacterial spectrum. First, S1 and S2, which had higher value of H (H represented the total hydrophobicity (sum of all residue hydrophobicity indices) divided by number of residues), showed lower antimicrobial activity against the Gram-negative *E. coli* demonstrated that the hydrophobicity of cysteine (C) or tyrosine (Y) was too high for this sequence, which might prevent these two peptides from transporting through non-specific transmembrane water-filled channels (or pores) of outer membrane of Gram-negative ([@B30]). Additionally, the non-activity of S3 indicated that the hydrophilicity of S3 might be not enough to break down the bacterial membrane because the high hydrophilicity of asparagine (N) decreased the total hydrophobicity of S3. The comparison of S5 and S7 with S6 demonstrated that this selectivity might be related to the folding structure of the final sequence affected by Glycine (G), which was following that a glycine-rich composition could facilitate flexibility or dynamicity and induced specifically antibacterial activity against Gram-negative bacteria ([@B10]). Thus, the comparison of seven hydrophilic amino acid peptides that had the same positive charge and hydrophobic amino acid composition indicated that the antimicrobial spectrum can be regulated by selecting different types of hydrophilic amino acids, which was in accordance with that the hydrophilic--hydrophobic balance of antimicrobial polymer significantly affects the interactions between the micelles and cell membrane ([@B7]).

Electrostatic adsorption with the negatively charged surface of a microorganism is the basis for the selectivity of cationic peptides, which will be inhibited by charge screening effects or competitive binding of some free ions, such as monovalent cations (Na^+^ and K^+^), divalent cations (Ca^2+^ and Mg^2+^) and multivalent cations (Fe^3+^) in the surrounding medium. In contrast, it was also reported that additional divalent cations could enhance the adsorption capacity of AMPs to the bacterial surface ([@B14]; [@B3]). Thus, it was hypothesized that the proportion of AMP and cation concentrations was increased. In our study, both S5 and S7 maintained their antimicrobial activities against pathogenic bacteria in the presence of salt (except for Fe^3+^) due to having enough positive charge or Trp composition, which could induce deep penetration of the peptides into the bacterial membrane and large membrane-bound surface area ([@B47]; [@B35]). To further confirm whether S5 and S7 could prevent or slow bacteria from becoming resistant, an evolution study of *E. coli* ATCC 25922 with sequential passaging was performed, and these drug resistance results forcefully proved that S5 and S7 are not affected by traditional mechanisms of bacterial resistance.

Antimicrobial peptides, which are regarded as the antibiotic substitute with the most potential for being not affected by traditional mechanisms of bacterial resistance, lead to cell death by physical disruption of the pathogen's membrane and subsequent leakage of cytoplasmic components, which greatly reduces the development of resistance against drugs ([@B26]; [@B45]; [@B39]; [@B18]). Thus, the antibacterial mechanisms of S5 and S7 were further confirmed by testing the interaction of peptides with lipopolysaccharide (LPS), lipoteichoic acid (LTA) and the cytoplasmic membrane (CM), the major components related to the mechanism of action of antimicrobial peptides. Negatively-charged lipopolysaccharides (LPS) or lipoteichoic acids (LTA) may interact with peptides via charge residues, which could attract antimicrobial peptides to increase the hydrophobic interaction, thereby increasing their antimicrobial effects ([@B32]; [@B6]; [@B31]). In this study, S5 and S7 showed lower binding affinity to LPS and LTA than to that of the broad-spectrum antimicrobial peptide melittin. Followed by the lower cytoplasmic membrane depolarization and the release of cytoplasmic β-galactosidase results of S5 and S7 compared with melittin. It was suggested that S5 and S7 could destroy the integrity of the cell membrane of the pathogenic bacteria, and the selectivity of S5 and S7 against pathogenic bacteria rather than probiotic bacteria might be due to the slight membrane damage effect. SEM, TEM, and CLSM results directly demonstrated that S5 and S7 can bind to bacterial membrane and cause obvious damage to the bacterial membrane, including blebbing of the outer membrane, pore formation in the cell membrane and leakage of intracellular contents, suggesting that S5 and S7 exert their bactericidal effects through mainly the action associated with membrane disruption. Additionally, there are indications that S5 and S7 could also induce accumulation of reactive oxygen species (ROS) in *E. coli* and *S. aureus*. These bactericidal mechanisms have little or no potential for selection of resistance, as the development of resistance would require an extraordinary number of mutations involving genes coding for pathways that generate bacterial cell wall architecture ([@B34]).

To date, most AMPs still display strong antimicrobial activity *in vitro* with slight or no activity *in vivo*. Thus, the application potential of the selected peptide was tested using a bacteria-infected mouse model. In this model, treatment was performed 1 h after inoculation, as 1 h is sufficient to allow bacteria to disseminate throughout the host ([@B50]; [@B22]). Our bacterial load data showed that S7 had effective therapeutic activity, reducing the bacterial load in the mice compared with that the *E. coli*-injected mice. In addition, the inflammatory cytokine level in serum was also tested because it reflects the outcome and severity of the infection ([@B46]; [@B24]; [@B11]). The result that the release of TNF-α and IL-6 was significantly decreased after S7 treatment suggested that the peptide might suppress the development of a cytokine storm via a rapid bactericidal effect *in vivo*, demonstrating that S7 is a promising therapeutic agent against bacterial infections in the clinical settings.

In this study, we proposed a series of triplet-tryptophan-pivot peptides and presented evidences of the effect that different hydrophilic amino acids had on peptide antimicrobial spectrum. These peptides showed high biocompatibility and retained antimicrobial activity in the presence of salt due to the high composition of tryptophan. The higher activity of S5 and S7 against pathogenic bacteria vs. probiotic bacteria showed the benefit of choosing threonine and serine. The membrane destruction of these peptides demonstrated that they have great potential to replace antibiotics with little potential for the development of resistance and long-lasting protective effects. Meanwhile, S7 displayed strong effective antimicrobial potency in a mouse model. Taken together, our studies not only analyzed the functions of hydrophilic amino acids on antimicrobial activity but also expanded the design method to develop bacteria-selective peptides.

Data Availability Statement {#S5}
===========================

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

Ethics Statement {#S6}
================

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the Animal Care and Use Committee of Northeast Agricultural University.

Author Contributions {#S7}
====================

SC and AS designed the research. QL, ZN, LS, JZL, and JWL performed the research. ZW and JWL performed analyses. All the authors have read and approved the manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** We gratefully acknowledge the financial support from the National Natural Science Foundation of China (31672434, 31872368, and 31472104), the China Agriculture Research System (CARS-35), and the Natural Science Foundation of Heilongjiang Province (TD2019C001).

[^1]: Edited by: Octavio Luiz Franco, Catholic University of Brasilia (UCB), Brazil

[^2]: Reviewed by: Giuseppantonio Maisetta, University of Pisa, Italy; Koshy Philip, University of Malaya, Malaysia

[^3]: This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
